"Receiving this patent is another important milestone, as China YCT accelerates its strategic growth plan," said Mr. Yan. "We're committed to developing innovative products based on our experience in the gingko healthcare products industry. We intend this to be the first in a series of technological breakthroughs, and we will continue to seek legal protection for these innovations. The benefits of our new products enhance the value of the Company as a whole," Mr. Yan added.
About China YCT International Group, Inc.
Established in 2005, China YCT International Group, Inc., through its operating subsidiary, Shandong Spring Pharmaceutical Co. Ltd., a corporation organized under the laws of the People's Republic of China, is a high-tech enterprise, which applies modern biological technology and integrates research & development, production and sales of ginkgo healthcare products, ginkgo cosmetics, daily-use chemical products, ginkgo glycoside products and biological medicines.
Safe Harbor Statement
The statements contained herein that are not historical facts are
"forward-looking statements" within the meaning of Section 21E of the
Securities and Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements may be
identified by, among other things, the use of forward-looking terminology such
as "believes," "expects," "may," "will," "should" or "anticipates" or the
negative thereof or other variations thereon or comparable terminology, or by
discussions of strategy that involve risks and uncertainties. In particular,
our statements regarding the potential growth of the markets are examples of
such forward-looking statement
|SOURCE China YCT International Group, Inc.|
Copyright©2010 PR Newswire.
All rights reserved